Topical presbyopia options differ in reported efficacy, duration, and adverse-effect profiles, according to an expert review of phase 3 data and clinical considerations presented at the 2026 American Academy of Optometry meeting.

Statin use was associated with lower open-angle glaucoma incidence and fewer glaucoma procedures in a large retrospective matched cohort, although the observational design did not establish a protective or causal effect.

The FDA warned that counterfeit over-the-counter eye drops found in several states may contain bacterial contamination capable of causing serious ocular infections. No associated adverse events had been reported when the warning was issued.

Ophthalmologists described using conversational AI for cataract assessments, patient education, and postoperative symptom monitoring at AAO 2026, while emphasizing that clinical validation, safety safeguards, and physician oversight remain essential as these tools enter practice.

Ocular discomfort persisted or emerged years after severe COVID-19 in a small longitudinal cohort despite few measurable ocular-surface differences between symptomatic and asymptomatic groups, suggesting mechanisms beyond conventional surface abnormalities may contribute.

The FDA approved RayOne Galaxy and RayOne Galaxy Toric for US commercial availability following a multicenter IDE study of more than 250 patients, expanding presbyopia-correcting IOL options for cataract surgeons.